Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.36
OCUL's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: 1.36 )
OCUL' s 10-Year Cash to Debt Range
Min: 1.36   Max: No Debt
Current: 1.36

Equity to Asset -2.90
OCUL's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: -2.90 )
OCUL' s 10-Year Equity to Asset Range
Min: -2.9   Max: 0.74
Current: -2.9

-2.9
0.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -12709.68
OCUL's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: -12709.68 )
OCUL' s 10-Year Operating margin (%) Range
Min: -136710   Max: -136710
Current: -12709.68

Net-margin (%) -13298.39
OCUL's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: -13298.39 )
OCUL' s 10-Year Net-margin (%) Range
Min: -140930   Max: -140930
Current: -13298.39

ROA (%) -68.78
OCUL's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: -68.78 )
OCUL' s 10-Year ROA (%) Range
Min: -69.55   Max: -55.74
Current: -68.78

-69.55
-55.74
ROC (Joel Greenblatt) (%) -1368.06
OCUL's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: -1368.06 )
OCUL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1741.53   Max: -1427.32
Current: -1368.06

-1741.53
-1427.32
» OCUL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OCUL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 2012.60
OCUL's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: 2012.60 )
OCUL' s 10-Year P/S Range
Min: 0   Max: 11142.1
Current: 2012.6

0
11142.1
Current Ratio 5.03
OCUL's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: 5.03 )
OCUL' s 10-Year Current Ratio Range
Min: 5.03   Max: 6.68
Current: 5.03

5.03
6.68
Quick Ratio 5.01
OCUL's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. OCUL: 5.01 )
OCUL' s 10-Year Quick Ratio Range
Min: 5.01   Max: 6.63
Current: 5.01

5.01
6.63

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare: » details
» More Articles for NAS:OCUL

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

More From Other Websites
Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment... Sep 16 2014
Ocular Therapeutix to Present at Morgan Stanley 2014 Global Healthcare Conference Sep 03 2014
OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 29 2014
Ocular Therapeutix Announces Second Quarter 2014 Financial Results Aug 28 2014
Ocular Therapeutix Announces Exercise of Over-Allotment Option Aug 19 2014
Coverage initiated on Ocular Therapeutix by RBC Capital Mkts and Oppenheimer Aug 19 2014
Ocular Therapeutix (NASDAQ: OCUL) to Ring The NASDAQ Stock Market Closing Bell Jul 31 2014
Ocular Therapeutix Announces Closing of Initial Public Offering Jul 30 2014
OCULAR THERAPEUTIX, INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Jul 30 2014
Stocks drop as Amazon and other earnings report disappoint Jul 25 2014
IPO Stock Watch: Biotechs Struggle To Get Out Door Jul 25 2014
IPOs Gear Up But See Tepid Pricing Jul 25 2014
IPOs off to damp start (again) ahead of tidal wave Jul 25 2014
IPO Preview: Ocular Therapeutix Jul 25 2014
Ocular Therapeutix Prices Initial Public Offering Jul 24 2014
IPO Stock Watch: Biotechs Are Half Of July Calendar Jul 23 2014
July Biotech Blitz And The Upcoming Eye, Ear And Nose IPOs Jul 23 2014
Watch Closely For Ocular Therapeutix IPO Jul 23 2014
IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment? Jul 21 2014
IPO Calendar: Biotechs Sizzle With 7 New Issues Jul 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK